Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
Cystic fibrosis (CF) is the most common genetic disorder among Caucasians, estimated to affect more than 70,000 people in the world. Severe and persistent bronchial inflammation and chronic bacterial infection, along with airway mucus obstruction, are hallmarks of CF lung disease and participate in...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01096/full |
id |
doaj-8b5f978c7d3a4c3cb3025ba2c69b94ab |
---|---|
record_format |
Article |
spelling |
doaj-8b5f978c7d3a4c3cb3025ba2c69b94ab2020-11-25T03:14:47ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-07-011110.3389/fphar.2020.01096557827Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative TherapiesChristie Mitri0Zhengzhong Xu1Zhengzhong Xu2Pauline Bardin3Harriet Corvol4Harriet Corvol5Lhousseine Touqui6Lhousseine Touqui7Olivier Tabary8Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, FranceSorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, FranceYangzhou University, Yangzhou, ChinaSorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, FranceSorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, FranceDépartement de Pédiatrie Respiratoire, Hôpital Trousseau, AP-HP, Paris, FranceSorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, FranceEquipe Mucoviscidose et Bronchopathies Chroniques, Département Santé Globale, Institut Pasteur, Paris, FranceSorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, FranceCystic fibrosis (CF) is the most common genetic disorder among Caucasians, estimated to affect more than 70,000 people in the world. Severe and persistent bronchial inflammation and chronic bacterial infection, along with airway mucus obstruction, are hallmarks of CF lung disease and participate in its progression. Anti-inflammatory therapies are, therefore, of particular interest for CF lung disease. Furthermore, a better understanding of the molecular mechanisms involved in airway infection and inflammation in CF has led to the development of new therapeutic approaches that are currently under evaluation by clinical trials. These new strategies dedicated to CF inflammation are designed to treat different dysregulated aspects such as oxidative stress, cytokine secretion, and the targeting of dysregulated pathways. In this review, we summarize the current understanding of the cellular and molecular mechanisms that contribute to abnormal lung inflammation in CF, as well as the new anti-inflammatory strategies proposed to CF patients by exploring novel molecular targets and novel drug approaches.https://www.frontiersin.org/article/10.3389/fphar.2020.01096/fullcystic fibrosisinflammationanti-inflammatorymucusantibiotic |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christie Mitri Zhengzhong Xu Zhengzhong Xu Pauline Bardin Harriet Corvol Harriet Corvol Lhousseine Touqui Lhousseine Touqui Olivier Tabary |
spellingShingle |
Christie Mitri Zhengzhong Xu Zhengzhong Xu Pauline Bardin Harriet Corvol Harriet Corvol Lhousseine Touqui Lhousseine Touqui Olivier Tabary Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies Frontiers in Pharmacology cystic fibrosis inflammation anti-inflammatory mucus antibiotic |
author_facet |
Christie Mitri Zhengzhong Xu Zhengzhong Xu Pauline Bardin Harriet Corvol Harriet Corvol Lhousseine Touqui Lhousseine Touqui Olivier Tabary |
author_sort |
Christie Mitri |
title |
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies |
title_short |
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies |
title_full |
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies |
title_fullStr |
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies |
title_full_unstemmed |
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies |
title_sort |
novel anti-inflammatory approaches for cystic fibrosis lung disease: identification of molecular targets and design of innovative therapies |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-07-01 |
description |
Cystic fibrosis (CF) is the most common genetic disorder among Caucasians, estimated to affect more than 70,000 people in the world. Severe and persistent bronchial inflammation and chronic bacterial infection, along with airway mucus obstruction, are hallmarks of CF lung disease and participate in its progression. Anti-inflammatory therapies are, therefore, of particular interest for CF lung disease. Furthermore, a better understanding of the molecular mechanisms involved in airway infection and inflammation in CF has led to the development of new therapeutic approaches that are currently under evaluation by clinical trials. These new strategies dedicated to CF inflammation are designed to treat different dysregulated aspects such as oxidative stress, cytokine secretion, and the targeting of dysregulated pathways. In this review, we summarize the current understanding of the cellular and molecular mechanisms that contribute to abnormal lung inflammation in CF, as well as the new anti-inflammatory strategies proposed to CF patients by exploring novel molecular targets and novel drug approaches. |
topic |
cystic fibrosis inflammation anti-inflammatory mucus antibiotic |
url |
https://www.frontiersin.org/article/10.3389/fphar.2020.01096/full |
work_keys_str_mv |
AT christiemitri novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT zhengzhongxu novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT zhengzhongxu novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT paulinebardin novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT harrietcorvol novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT harrietcorvol novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT lhousseinetouqui novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT lhousseinetouqui novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies AT oliviertabary novelantiinflammatoryapproachesforcysticfibrosislungdiseaseidentificationofmoleculartargetsanddesignofinnovativetherapies |
_version_ |
1724642440152875008 |